New drug trial offers hope when lung cancer outsmarts standard treatment
NCT ID NCT07158840
Summary
This study is testing an investigational drug called AK112 for people with advanced non-squamous lung cancer. It is for patients whose cancer has a specific genetic change and has stopped responding to standard targeted pills (TKIs). The main goal is to see if AK112 can shrink tumors and control the cancer's growth, while also monitoring side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, China
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.